Lixte Biotechnology (NASDAQ:LIXT) Trading Up 3.9% – Should You Buy?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)’s stock price was up 3.9% during mid-day trading on Wednesday . The stock traded as high as $3.43 and last traded at $3.16. Approximately 133,437 shares were traded during trading, an increase of 101% from the average daily volume of 66,363 shares. The stock had previously closed at $3.04.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lixte Biotechnology in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Lixte Biotechnology Stock Up 3.9%

The firm has a market capitalization of $23.64 million, a price-to-earnings ratio of -2.68 and a beta of 0.94. The company’s fifty day moving average is $3.97 and its two-hundred day moving average is $4.24.

Lixte Biotechnology (NASDAQ:LIXT) last released its earnings results on Wednesday, November 12th. The company reported ($0.33) EPS for the quarter.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.